Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Preclinical studies in animal models have yielded several noteworthy findings
& Brouwer, A
All improvements reversed after 12 weeks of stopping supplementation, suggesting ongoing use is required
Interpretation of metabolic memory phenomenon using a physiological systems model: what drives oxidative stress following glucose normalization
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
US$ 23.57
US$ 23.70
US$ 20.89
US$ 27.74
US$ 22.32
US$ 28.26
